Member Info for Leggster

At least we know this is the final position. Hopefully better news from here onwards, always high risk high reward, the science continues to progress. I am looking at the positives rather than the negatives. GLA

I agree nice to see a rise and hopefully will be steady as we progress through the news, MAD should be announced if HBD estimate proves right (and his research on the Aus trials has been great so far), then 737 news and then announcements on 1801 licence or partner. I personally would not payoff RF until Aug 2025. Why give them the early cash flow after the damage done to the SP. GLA

Signed, defo should not be allowed outside of large MCap

I agree the finance situation has been abysmal but the science has been progressing, slower than ideal but we are very much on the cusp, I agree that the BOD were probably naively expecting 737 to deliver value earlier, but news should be coming on that front and MAD will finish shortly. As has been rightly said we are not a new molecule but we are 2nd generation with hopefully a significantly better safety profile, these results will be available this quarter and deal discussions can start. IMO this could result in a licence deal or TO. I feel the later is most likely given our low MCap, the open question in my mind is how much news we can release before that happens to drive the SP up and then achieve a decent multiple. Whether a TO or a licence we clearly though need multiple interested parties to get the best return, let's hope that there's 'a queue'. Anyway wishing SAR a far more positive new tax year than last. GLA

Feel the updates today were needed, after the disaster for the SP that was RF this IMO should mark the bottom and we can start to rebuild. Have purchased some more today to level down at these prices and will subscribe to the WRAP. Pleased to see the rapid timeframe as the new tax year and fairly imminent news gives an opportunity for some upwards momentum. Director salary deferment and participation in the rise I see as needed to show confidence. Also pleased with comments on the trials. I feel more certain than ever that they plan to licence before 1801. I do though feel that the last few months will have taken a toll on the BOD, I think that the chance that they will sell out has increased materially, They are scientists and reading the bulletin boards comments and suffering the stress of the SP decrease must make them think seriously about an exit. Hopefully though the data will be strong and there will be a number of suitors. GLA

Agree with Laz thanks for finding the time to head up there. I too also hope Tim is busy in meetings. But if not and he glances at this board perhaps he should take the time to have a pub lunch, good luck

I agree here silence is hopefully positive and I fully agree with you Potnak that Tim and John's own vested interest is to drive the SP back up. I personally always felt a deal between 1a and 1b was the most probable outcome but to achieve the best outcome we need good results from 1a on to keep our fingers crossed that there is more than 1 interested party in getting hold of 1801. GLA

Encouraging to see some chunky buys going through this morning, hopefully news shortly on the completion of MAD and some updates on finance arrangements, GLA

Pleasing to see the RNS today, more protection adds value but as many have already said the language in quote is far more positive than often used. Let's hope the shock of RF and recent events has changed the approach to comes ongoing. GLA

I am also inclined to leave the BOD as is at this point in time. Changes now would not IMO create a greater chance of a successful negotiation of the current choppy waters. Always a high risk investment but I do admit I expected the rollercoaster from the science rather than the finances, live and learn I suppose. GLA

I would also be prepared to be involved. Prospects here are too good to allow us to be driven to accept low ball offers. GLA

Potnak, I really do hope we see some more RNS releases in fairly short order, I am still of a mind that the BOD will be working non stop to find a way through to solve these problems, their own holdings and significant intellectual and I am sure emotional investment to get to this point will ensure they do all they can to restore the SP. Does though read from the tone of the RNS that deep cuts are needed with immediate effect to enable completion of 1a, I have my fingers crossed that there are multiple parties interested in 1801 to ensure that we get fair value from a deal. I fear that 1801 may have to licenced at less than fair value to keep the business going and deliver a platform for 1802 to be developed from. As I said earlier really do not want to see a sale if their stake in 737. GLA

Yes very trying news, worrying that this has been issued without details of alternate financing being included, really hope a raise or HNWI and not a firesale of 737. Salary deferment for shares would send a positive sign of BOD confidence. Further action by the BOD eg director buys would also be appropriate, very disappointing so close to 1a finishing. GLA

Would be fascinating to know the BODs strategy at this point. Clearly they will want to exit RF as quickly as possible and the end of phase 1a is imminent. I personally feel they will look for a deal on 1801 after 1a completes, for me this frees them from RF it removes the overhead of running 1b and then combined with 737 gives them the cash runway to move 1802 forward. For me this fits with their published strategy and although not delivering the TO many would like to see creates a clear way forward. I don't disagree that other options exist and need to be explored in my model to allow low ball offers to be rejected. For me this is why BOD change is not at all desirable in a period of pivotal negotiation for SAR experienced individuals who have worked together over time is vital to getting the best outcome. GLA

Most of us expect news soon, so hopefully this SP will be a bad dream in the near future. GLA

Would a pleasant surprise if after the funding milestone the next is a first dosage milestone or submitted application for trial hopefully this time with no territory component like before.

HBD, I agree I think that first milestone being financial is helpful to SAR and IMO will probably be soon assuming the licencee moved to the raise quickly. What I wonder though is what the next milestones will be (or not) after that first step is reached. Are other milestone in the agreement trigger once a step is achieved.... GLA

Another week over, still no issues, MAD either complete or about to complete, 737 has been with its new caretakers for long enough that news could be due, and RF continuing selling low for now. Hopefully will get another news snippet or two to energise the SP over the coming weeks. I am still confident here and feel we can expect some good news in the due course of time. GLA

I do not see any advantages to BOD changes at this time, from my own perspective I am still fully supportive of all board members. Getting closer to the endgame on a daily basis, but patience is needed. GLA

To save everyone googling away the minutes in their day a brief history of Mei Pharma which all sounds encouraging

MEI Pharma: A Summary History

Founding and Early Years (2010-2014):

Formed in 2010 by Daniel Gold, Ph.D., with a focus on developing novel therapies for cancer.

Initially focused on acquiring and developing CDK inhibitors, a class of drugs targeting cell cycle regulation.

Secured funding through several venture capital rounds and grants.

Shifting Focus and Growth (2014-2023):

Expanded pipeline in 2014 with the acquisition of MEI Pharma (originally known as Mirabilis Pharmaceuticals).

Gained access to ME-344, a potential treatment for solid tumors, and Voruciclib, a CDK9 inhibitor.

Advanced both drugs through clinical trials, with Voruciclib reaching Phase 3 for acute myeloid leukemia (AML).

Focused on partnerships and collaborations with other pharmaceutical companies.

Recent Developments (2023-Present):

Presented positive clinical data on Voruciclib at the American Society of Hematology (ASH) annual meeting in December 2023.

Announced design of ongoing Phase 2 clinical study for ME-344 at the ASCO Gastrointestinal Cancers Symposium in January 2024.

Released 2023 annual report highlighting financial performance and operational progress.

Continued focus on developing best-in-class cancer therapies and improving patient outcomes.

Key Points:

Founded in 2010, MEI Pharma has grown from a small, research-focused company to a clinical-stage pharmaceutical entity.

The company primarily focuses on developing novel cancer therapies, particularly CDK inhibitors.

Its lead drugs, Voruciclib and ME-344, are currently in clinical trials for various cancer indications.

MEI Pharma is committed to partnerships, collaborations, and continuous development to bring innovative treatments to patients.